16.17
Fulgent Genetics Inc stock is traded at $16.17, with a volume of 433.71K.
It is up +0.94% in the last 24 hours and up +9.48% over the past month.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
See More
Previous Close:
$16.02
Open:
$16.03
24h Volume:
433.71K
Relative Volume:
0.87
Market Cap:
$466.42M
Revenue:
$322.67M
Net Income/Loss:
$-61.63M
P/E Ratio:
-8.2273
EPS:
-1.9654
Net Cash Flow:
$-124.21M
1W Performance:
+2.15%
1M Performance:
+9.48%
6M Performance:
-28.95%
1Y Performance:
-15.25%
Fulgent Genetics Inc Stock (FLGT) Company Profile
Name
Fulgent Genetics Inc
Sector
Industry
Phone
626-350-0537
Address
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
FLGT
Fulgent Genetics Inc
|
16.17 | 462.09M | 322.67M | -61.63M | -124.21M | -1.9654 |
|
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Upgrade | UBS | Neutral → Buy |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-18-22 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Feb-04-22 | Resumed | Piper Sandler | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Underperform |
| Jan-08-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-20-20 | Initiated | Oppenheimer | Outperform |
| May-29-20 | Initiated | BTIG Research | Buy |
| Nov-05-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Mar-01-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-07-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Fulgent Genetics Inc Stock (FLGT) Latest News
Stock Recap: Whats the analyst consensus on Fulgent Genetics Inc2026 Growth vs Value & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Pullback Watch: Is Fulgent Genetics Inc a momentum stock2026 Levels & Daily Momentum Trading Reports - baoquankhu1.vn
Stop Loss: Can Fulgent Genetics Inc stock outperform in a bear market2026 Biggest Moves & Risk Managed Investment Entry Signals - baoquankhu1.vn
Fulgent Genetics Inc (FLGT) Stock Down 3.9% -- Now Undervalued? GF Score: 64/100 - GuruFocus
Precision Trading with Fulgent Genetics Inc. (FLGT) Risk Zones - Stock Traders Daily
Buyback Watch: What is the long term forecast for Fulgent Genetics Inc stockEarnings Trend Report & Safe Entry Trade Signal Reports - baoquankhu1.vn
Can Fulgent Genetics Inc stock outperform in a bear marketTrade Risk Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Surprises Report: Can Fulgent Genetics Inc stock outperform in a bear market2026 Action & Accurate Buy Signal Alerts - baoquankhu1.vn
Hennion & Walsh Asset Management Inc. Makes New $1.74 Million Investment in Fulgent Genetics, Inc. $FLGT - MarketBeat
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, ... - Bluefield Daily Telegraph
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Dow Update: What are Fulgent Genetics Incs technical support levelsWeekly Stock Analysis & Risk Managed Investment Signals - baoquankhu1.vn
Aug Volume: What is the long term forecast for Fulgent Genetics Inc stockWeekly Loss Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
FLGT PE Ratio & Valuation, Is FLGT Overvalued - Intellectia AI
JPMorgan Chase & Co. Increases Position in Fulgent Genetics, Inc. $FLGT - MarketBeat
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc - ACCESS Newswire
Fulgent Genetics (NASDAQ: FLGT) CEO cancels 750,000-share prepaid forward - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) CEO reports 30.7% ownership stake - Stock Titan
[ARS] Fulgent Genetics, Inc. SEC Filing - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) outlines 2026 meeting, pay and equity plan votes - Stock Titan
Fulgent Genetics (FLGT) price target decreased by 27.72% to 24.82 - MSN
Short Interest in Fulgent Genetics Rises 38.7% - National Today
Technical Reactions to FLGT Trends in Macro Strategies - Stock Traders Daily
Short Interest in Fulgent Genetics, Inc. (NASDAQ:FLGT) Rises By 38.7% - MarketBeat
Fulgent Genetics Receives 'Hold' Rating from Analysts - National Today
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc. - lincolnjournal.com
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent ... - Bluefield Daily Telegraph
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. - marketscreener.com
If You Invested $1,000 in Fulgent Genetics (FLGT) - Stock Titan
Aug Weekly: How is Fulgent Genetics Inc managing supply chain issues2026 Technical Patterns & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Fulgent Genetics, Inc.Common Stock (NQ: FLGT - The Chronicle-Journal
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - GlobeNewswire Inc.
Fulgent Genetics Completes $56.9M Acquisition of Bako Diagnostics and StrataDx to Expand Precision Medicine Services - Minichart
Trading the Move, Not the Narrative: (FLGT) Edition - Stock Traders Daily
Published on: 2026-03-19 03:58:12 - baoquankhu1.vn
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx - BioSpace
Fulgent Genetics completes $56.9M pathology lab acquisitions By Investing.com - Investing.com Australia
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - Business Wire
Fulgent Genetics Acquires Bako Diagnostics Assets, StrataDx for $56.9 Million - marketscreener.com
Fulgent Genetics completes $56.9M pathology lab acquisitions - Investing.com
Fulgent Genetics Expands Dermatology Footprint With Key Acquisitions - TipRanks
Fulgent Genetics (NASDAQ: FLGT) buys Bako Diagnostics and StrataDx - Stock Titan
Fulgent Genetics (NASDAQ:FLGT) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Fulgent Genetics (FLGT) Stock Analysis Report | Financials & Insights - Benzinga España
Fulgent Genetics seeks new collaborations at Copenhagen ADPD2026 event - Traders Union
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics: A Major Market Misconception (NASDAQ:FLGT) - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.FLGT - PR Newswire
Fulgent Genetics Inc Stock (FLGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):